

Taking up the challenge — neuroischaemic diabetic foot ulcers

Galea E

ABSTRACT

Diabetic patients are at a high risk of amputations with most of these debilitating and life-threatening procedures being preceded by ulcers. Risk factors for the development of a foot ulcer in the diabetic patient include long diabetes duration, the presence of peripheral neuropathy, peripheral vascular disease, a history of any prior foot ulcer, and prior amputation. Moreover, recent medical forecasts have shown that neuroischaemic diabetic foot ulcers (DFUs) are on the increase worldwide. Health care professionals have a pivotal role to provide optimal management of DFUs, leading to a reduction in amputation rates. A TLC-NOSF (TLC-sucrose octasulfate) dressing has been shown in various clinical and observational studies that it may well play a key role in the local management of these wounds. The Explorer Study, conducted over six years in five European studies, has provided health care professionals with robust clinical evidence and it has been shown to have the potential to improve health outcomes and strengthen health systems by providing more efficient and cost-effective care.

Keywords: Chronic wounds, diabetic foot ulcers, neuroischaemic diabetic foot ulcers, TLC-NOSF, Explorer Study.

AIMS

The aims of this paper are threefold:

- To discuss the severity of the problem of diabetic foot ulcers (DFUs), mainly neuroischaemic and its implications, while exploring the complexity of these types of wounds.
- To evaluate the effectiveness of TLC-NOSF (Technology Lipido-Colloid — Nano OligoSaccharide Factor) in the management of chronic wounds through results of previously published randomised controlled trials (RCTs) and explore the methods and results of a recent RCT regarding the specific management of neuroischaemic DFUs.

Emilio Galea

RN (Malta), MSc Skin Integrity Skills & Treatment
(University of Hertfordshire, UK)
International Medical Director, URGO International
Email e.galea@intl.urgo.com

- To assess the reactions regarding the Explorer Study and how the results may affect the way DFUs are managed.

INTRODUCTION

Diabetes has been stated as the most common cause of non-traumatic lower limb amputations¹ and understanding mortality rates of these non-traumatic amputations sheds an appalling truth on the severity of the consequences of DFUs². In his blog, David Armstrong aptly stated that “Perhaps the reason these sobering data are so sobering is because the ‘hole’ is a window on the ‘whole’”. In other words, the ulcer on the foot is likely a better predictor than any of the other end organ diseases because it is an amalgam of all of those complications in one place². The data referred to comes from a study conducted by Brennan *et al.*, who concluded that 1-, 2-, and 5-year survival rates were 80.80%, 69.01% and 28.64%, respectively³, while it was also presented that people with a history of a DFU, have a 40% greater 10-year mortality than people with diabetes alone⁴.

The facts about DFUs are really ‘sobering’ and these have highlighted the importance of acting as early as possible to avoid further complications, such as amputations. The earlier recognition of the high-risk foot and the timely treatment is said to save both the limbs and lives of diabetic patients⁵. DFUs require aggressive management involving a coordinated interprofessional team⁵. Appropriate management of DFUs cannot be overstressed, making it vital that clinicians are able to make informed, evidence-based decisions on the optimal management strategy⁶.

THE NEUROISCHAEMIC DFU.

The annual population-based incidence of DFUs ranges from 1.0% to 4.1%, with a lifetime incidence that may be as high as 25% globally⁷, with lifetime prevalence that is now estimated to be 19–34%⁸. The presence of peripheral vascular disease (PVD) is a strong predictor of non-healing foot ulcers⁹, with diabetic patients being more at risk, as they have more severe disease in the distal arteries than those without diabetes¹⁰. This is mainly attributed to the issue that diabetes mellitus is concomitant with advanced atherosclerosis, with extended arterial wall calcifications and occlusions in lower limb arteries¹¹.

In the 1980s, it was suggested that neuropathy was the main factor responsible for foot ulceration in diabetes¹²; however, this is contrasted by more recent suggestions that there has been a noticeable increase of foot ulcers with underlying

PVD, with 52.3% of all ulcers being neuroischaemic, 36% neuropathic, and 11.7% purely ischaemic¹³. Neuroischaemia is the result of a combination of the effects of both neuropathy and ischaemia¹⁴ and develops ulcers on the margins of the foot and toes, often located at sites of pressure from poorly fitted shoes¹⁵ with pressure going unperceived due to the co-existing neuropathy¹⁶. It is not clearly understood why there is this increase of neuroischaemic and ischaemic ulcers in diabetic patients; however, it has been speculated that this is mainly due to better diagnostic methods and stricter diagnostic criteria as well as an increased awareness on the role of ischaemia to foot ulceration, leading to better systematic screening and diagnosis of PVD⁶.

Management of the neuroischaemic foot has been identified as treating the underlying disease processes, relief of pressure (off-loading), debridement and hyperkeratosis removal, revascularisation when possible and management of inflammation and infection¹⁷⁻¹⁹.

Although neuroischaemic ulcers have been established today as the most common DFUs, no clinical studies have ever assessed the performances of any device or procedure in a cohort of patients exclusively presenting with neuroischaemic ulcers²⁰ and, thus, no device or drug has demonstrated efficacy in neuroischaemic DFU treatment²¹.

THE NEUROISCHAEMIC DFUs AND THEIR MICRO-ENVIRONMENT

The complexity of neuroischaemic ulcers has been recently explored in greater detail and issues such as fibroblast dysfunction, poor neo-vascularisation and high levels of metalloproteinases (MMPs) have been identified as prolonging the inflammatory process and delaying healing²².

MMPs are part of the structurally related, protein-degrading enzymes that require calcium ions for structural conformation and zinc ions in their active site for function²³. Their main purpose in wound healing is tissue degradation — they are usually produced in response to tissue injury and are not normally present in detectable levels in healing and non-injured tissue²⁴. They degrade substances in the extracellular membrane (ECM) in order to facilitate migration of cells, deposition of new ECM as well as the development of new tissue²⁴. The activity of MMPs is controlled at three basic levels: (1) at the gene level by transcriptional control; (2) at the molecular level by requiring factors to convert the proenzyme form to the active form; and (3) through local secretion of endogenous enzyme tissue inhibitors of metalloproteinases (TIMPs)^{23,24}.

MMPs appear to be elevated in chronic wounds and they may play a role in determining the chronicity of these wounds²⁵. There is a significantly higher degradation of epidermal growth factor in chronic wounds and chronic wound fluid has 30-times greater MMP activity when compared with acute wound fluid²⁶.

Neovascularisation is important for wound healing as it involves the growth of new capillaries to form granulation tissue²⁷. In diabetics, angiogenesis is decreased, with subsequent poor formation of new blood vessels and decreased entry of inflammatory cells and their growth factors²⁸. Moreover, growth factors essential for wound healing have been found to be reduced in experimental diabetic wounds models²⁹. Vascular endothelial growth factor (VEGF), which plays an important role in neovascularisation by stimulating angiogenesis as well as influencing wound closure and epidermal repair, granulation tissue formation, and the quality of repair, is also deficient in diabetic wounds as shown in an experimental and clinical model³⁰. In chronic wounds, the formation and release of growth factors may be prevented. Growth factors may be sequestered and unable to perform their metabolic roles, or degraded in excess by cellular or bacterial proteases³¹.

MANAGEMENT OF CHRONIC WOUNDS WITH A TLC-NOSF DRESSING

Sucrose octasulfate has been previously used in the management of gastro-duodenal ulcers³². However, this molecule has been shown to accelerate epithelial wound healing by increasing the bio-availability of certain growth factors, which, in turn, has been demonstrated to have a crucial role in angiogenesis^{33,34}. Sulfated oligosaccharides have many biological activities such as inhibition of matrix metalloproteinases and interaction with growth factors and restoring their biological functions³⁵⁻³⁷. Furthermore, nano-oligosaccharide factor (NOSF, sucrose octasulfate) is an innovative compound derived from the same chemical oligosaccharide family of sucrose octasulfate that has demonstrated MMP-inhibiting properties and clinical efficacy. It promotes healing in leg ulcers, pressure ulcers, DFUs and recurring wounds^{33,34}.

The efficacy of NOSF was tested *in vitro* and was shown that technology lipido-colloid (TLC)-NOSF significantly reduces the activity of MMPs, such as gelatinases (MMP2 and MMP9) and collagenases (MMP1 and MMP8) as well as stimulates the proliferation of fibroblasts, favouring wound healing and stimulating the formation of extracellular matrix by increasing collagen synthesis and hyaluronic acid synthesis³⁸⁻⁴². Initially, two clinical studies testing TLC-NOSF (UrgoStart® — Urgo Medical) were conducted: The Wound Healing Active Treatment (WHAT) study⁴³, and the Challenge Study⁴⁴. The WHAT study was an open, two-arm, parallel group, 12-week randomised trial conducted in 22 French hospital units and 5 UK wound specialised centres, with the intention to show non-inferiority or superiority of the NOSF matrix compared with a collagen-ORC dressing (PROMOGRAN™ Matrix Wound Dressing — Acelity). Both patient populations (117 patients were randomised: 57 and 60 patients in the NOSF matrix and control groups) had similar characteristics and venous leg ulcers (VLUs) at baseline. VLUs included in this clinical trial were considered as difficult-to-heal wounds: the mean age of the population was >70 years, ulcers were

present for 11 months on average and 61% were recurrent and the baseline mean ulcer area was superior by 10 cm². Regarding the primary objective (wound area reduction), the TLC-NOSF dressing reduced the wound surface area by 54.4% compared to 13.0% with the collagen-orc dressing during the 12-week period ($p=0.0286$). The healing rates were 5.5 mm²/day with TLC-NOSF and 1.5 mm²/day with collagen-orc ($p=0.029$). TLC-NOSF also reduced the size more wounds by >40%: 56.1% versus 35.0% with collagen-orc ($p=0.022$). Moreover, TLC-NOSF was found to have a better safety profile than collagen-orc. The Challenge Study was a controlled, randomised, phase 3, multi-centre, double-blind clinical trial. Overall, results clearly demonstrated a significant superiority and a sustained effect of the test dressing versus the control when considering relative and absolute wound area reduction over the eight-week treatment. The primary study outcome was the relative wound area percentage of wound area reduction, and the secondary objectives were absolute wound area reduction, healing rate, and percentage of wounds with >40% surface area reduction. One hundred and eighty-seven patients were randomly allocated to treatment groups. Screened patients were of both sexes, over 18 years of age (with no upper age limit), and were being managed for a VLU. Median wound area reduction was 58.3% in the TLC-NOSF dressing group and 31.6% in the TLC control group, with a difference: -26.7%; 95% confidence interval: -38.3 to -15.1%; $p=0.002$). All other efficacy outcomes were also significant in favour of the TLC-NOSF dressing group. Clinical outcomes for patients treated with the TLC-NOSF were shown to be superior to those patients in the control group (TLC without NOSF), suggesting a strong promotion of the healing process. Furthermore, a more recent publication reported the results from the same study assessing the performance and safety of TLC-NOSF in the local management of VLUs or mixed leg ulcers and determining its impact on the patient's health-related quality of life (HRQoL)⁴⁵. In the HRQoL questionnaire (EQ-5D), the pain/discomfort and anxiety/depression dimensions were significantly improved in the TLC-NOSF group versus the control one (pain/discomfort: 1.53 ± 0.53 versus 1.74 ± 0.65 ; $p=0.022$, and anxiety/depression: 1.35 ± 0.53 versus 1.54 ± 0.60 , $p=0.037$). The visual analogue scale score was better in the test group compared with the control group (72.1 ± 17.5 versus 67.3 ± 18.7 , respectively). Acceptability and tolerance of the two products were similar in both groups.

Interestingly, a 2014 cost-effectiveness analysis derived from the clinical study 'Challenge' from the perspective of the German statutory health care system was performed using a decision tree model for a period of eight weeks⁴⁶. In the treatment model, effect-adjusted costs of €849.86 were generated after eight weeks for treatment of the patients with VLUs with TLC-NOSF versus €1335.51 for the comparator, resulting in an effect-adjusted cost advantage of €485.64 for TLC-NOSF. In linear sensitivity analyses, the outcomes were stable for varying assumptions on prices and response rates, showing superior cost-effectiveness of the TLC-NOSF when

compared with the similar neutral foam dressing without any active component (TLC without NOSF).

Moreover, an analysis by pooling the data from real-life observational studies on chronic wounds treated with TLC-NOSF wound dressings was conducted to determine whether the clinical trials' results translate into routine management of such wounds⁴⁷. Pooled data from eight European observational studies (10,220 patients with various chronic wounds) were analysed to see if the clinical data from RCTs could be extrapolated to daily practice. Time to complete wound closure and time to 50% reduction in pressure ulcer scale for healing score using the Kaplan–Meier model (estimation of average time to closure) and subgroup analysis (depending on the Margolis severity score) were assessed.

In total, data from 10,220 patients were included, with 7903 leg ulcers (LUs), 1306 DFUs and 1011 pressure injuries (PIs). The overall closure rate was 30.8% [95% confidence interval (CI): 29.9–31.7%]. Overall, the average time to complete closure was 112.5 days [95% CI: 105.8–119.3] for LUs, 98.1 days [95% CI: 88.8–107.5] for DFUs and 119.5 days [95% CI: 94.6–144.3] for PIs. Based on a subgroup analysis of the French cohort, time to closure is substantially shorter for wounds treated with the TLC-NOSF dressing as a first-line intervention compared with those where it has been prescribed as a second-line intervention.

MANAGEMENT OF NEUROISCHAEMIC DFU WITH TLC-NOSF DRESSING

An initial pilot, prospective, multi-centre, non-controlled pilot, open-label trial of TLC-NOSF was conducted to test it in the management of DFUs³⁴. The cohorts ($n=34$) included adults with a grade 1A (Texas classification) uninfected neuropathic foot ulcer 1–15 cm² in size with a duration of 1–24 months (mean 6.7 ± 5.2 months). The primary endpoint was relative reduction in wound surface area (%). The results showed an 82% median surface reduction by week 12. Ten patients' DFUs (31.3%) had healed during this period³⁴. These results seemingly compare favourably with those from the literature achieved after a systematic review of 10 RCTs. The investigators concluded that TLC-NOSF matrix (UrgoStart® Contact) could be an interesting adjunct in the therapeutic treatment of these chronic wounds.

The announcement made in 2013 by Urgo Medical of the pioneering Explorer Study into the efficacy of UrgoStart® Contact for treating DFUs was an exciting development in the management of these potentially devastating wounds⁴⁸. It was established that there was a lack of firm evidence for the efficacy of dressings in the local management of DFU. The Explorer study was designed to make a major contribution to the evidence base in this field⁴⁸. As such, it was expected that this study will bring a much-needed element of clinical consistency to the decision-making process in this challenging arena⁴⁸.

The Explorer Study³³ set out to test the efficacy of TLC-NOSF dressing versus a control (TLC dressing without NOSF) dressing in patients with neuroischaemic DFUs. This was the first study to assess the efficacy of a dressing in individuals with diabetes and confirmed neuropathy and PVD. The double-blind trial was conducted in five European countries across 43 hospital centres with specialised diabetic foot clinics using a multidisciplinary approach. The eligible 240 participants were inpatients or outpatients, aged 18 years or older with diabetes and a non-infected neuroischaemic DFU >1 cm² and of grade IC or IIC (University of Texas Diabetic Wound Classification system). The participants were randomly assigned using a computer-generated randomisation procedure to treatment with either a sucrose octasulfate wound dressing (UrgoStart[®]) or a control dressing without sucrose octasulfate (UrgoTul[®]) for 20 weeks. The two cohorts received the same standard of care for a two-week screening period before randomisation and throughout the 20-week trial and then were assessed two weeks after randomisation, then monthly until week 20 or occurrence of wound closure. The primary outcome, assessed by intention-to-treat, was the proportion of patients with wound closure at week 20. The noteworthy result of this study showed that wound closure occurred in 60 patients (48%) in the sucrose octasulfate dressing group versus 34 patients (30%) in the control dressing group (18 points difference, 95% CI 5–30; adjusted odds ratio 2.60, 95% CI 1.43–4.73; $p=0.002$). The assessed mean time to closure was 60 days (95% CI 47–75) longer in the control dressing group than in the TLC-NOSF dressing group. A greater reduction in absolute wound surface area and in relative wound surface area, and a faster wound re-epithelialisation wave were recorded in the TLC-NOSF cohort than in the control group by week 20. Also of note is that, in the TLC-NOSF group, 65% (46/71) of wounds with a duration of <6 months, closed compared to just 25% (14/55) of wounds \geq 6 months. This strongly suggests that earlier adaptation of UrgoStart[®], in addition to accepted standards of care, for example, offloading, debridement, affords better results. The Explorers concluded that: “A sucrose octasulfate dressing is effective and safe, and its use is easy to implement by all health-care professionals. This dressing could form an important part of modern multidisciplinary management of neuro-ischaemic diabetic foot ulcers.”

The use of several offloading devices was considered a limitation of this study. It was decided to use several devices rather than one specific device due to the practices of the 43 centres with different experience with and access to specific devices.

Reactions to the Explorer RCT have been very positive. Pr Fran Game (NHS, UK) was quoted as saying that “the results are certainly more encouraging than findings for most interventions that have been reported to date”⁴⁹. However, Dr Edmonds emphasises that the findings are relevant to patients with neuroischaemic DFUs and not critically ischaemic feet,

for which urgent revascularisation is required⁴⁹. Furthermore, DFA stated that “Overall, the methodological rigour of this study really sets the standard for future wound dressing studies to achieve. With the quality of this study and its findings we dare say that the new International Guidelines (launched at the International Symposium on the Diabetic Foot in May 2019) will feature a new recommendation, something like ‘to heal a neuroischaemic diabetic foot ulcer consider using a sucrose octasulfate impregnated dressing.’”⁵⁰

CONCLUSION

Quality research needs to be translated into the clinical environment to ensure that health care professionals have sound clinical evidence upon which to base their clinical management. The application of evidence-based practice has been shown to have the potential to improve health outcomes and strengthen health systems by providing more efficient and cost-effective care. The Explorer Study has provided health care professionals who face the challenge of neuroischaemic DFUs in their daily practice with the evidence that can be a paradigm shift in how these hard-to-heal wounds are managed. It has been shown in the RCTs quoted, that, together with evidence-based standard of care, UrgoStart[®] is a safe and reliable option in the management of chronic wounds in general. Moreover, the Explorer Study has provided clinicians with robust evidence regarding the benefits and efficacy of UrgoStart[®] in the management of diabetic neuroischaemic foot ulcers.

DISCLAIMERS

The author is the International Medical Director of URGO Medical. The RCTs discussed regarding TLC-NOSF in this paper are suggested to be unbiased publications by independent authors.

REFERENCES

1. Rogers LC, Bevilacqua NJ. Organized programs to prevent lower-extremity amputations. *J Am Podiatr Med Assoc* 2010 Mar;100(2):101–4.
2. Armstrong D. 1, 3 and 5 year survival after a diabetic foot ulcer is 80%, 69% and 29%. 2016 Dec DF Blog. Accessed 20/04/18. Available from: https://diabeticfootonline.com/2016/12/19/1-3-and-5-year-survival-after-a-diabetic-foot-ulcer-is-80-69-and-29/?utm_sq=fc6ammjrcn&utm_source=Twitter&utm_medium=social&utm_campaign=dgarmstrong&utm_content=Facts
3. Brennan MB, Hess TM, Bartle B *et al.* Diabetic foot ulcer severity predicts mortality among veterans with type 2 diabetes. *J Diabetes Complications* 2017 Mar 1;31(3):556–61.
4. Iversen MM, Tell GS, Riise T *et al.* History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the Nord-Trøndelag Health Study, Norway. *Diabetes Care* 2009 Dec 1;32(12):2193–9.
5. Alavi A, Botros M, Kuhnke JL. Diabetic foot: disease, complication or syndrome. *Diabetic Foot Canada* 2013;1:13–7.
6. Ndip A, Jude EB. Emerging evidence for neuroischemic diabetic foot ulcers: model of care and how to adapt practice. *Int J Low Extrem Wounds* 2009 Jun;8(2):82–94.

7. Van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. *Eur J Cardiovasc Prev Rehabil* 2010 May;17(suppl.1):s3–8.
8. Armstrong DG, Boulton AJM, Bus SA: Diabetic Foot Ulcers and Their Recurrence. *New Engl J Med* 2017;376(24):2367–2375.
9. Prompers L, Schaper N, Apelqvist J *et al.* Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. *Diabetologia* 2008;51:747–755.
10. Prompers L, Huijberts M, Schaper N *et al.* Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the EURODIALE Study. *Diabetologia* 2008;51:1826–1834.
11. Alexandrescu V. Is Limb Loss Always Inevitable for Critical Neuro-Ischemic Foot Wounds in Diabetic Patients with End Stage Renal Disease and Unfit for Vascular Reconstructions? *Diseases of Renal Parenchyma*, Prof. Manisha Sahay (Ed.), ISBN: 978-953-51-0245-8, InTech, Available from: <http://www.intechopen.com/books/diseases-of-renal-parenchyma/is-limb-loss-always-inevitable-for-criticalneuro-ischemic-foot-wounds-in-diabetic-end-stage-renal-d>. Accessed 21/04/18.
12. Rothman KJ. *Modern Epidemiology*. Boston, MA: Little, Brown & Company, 1986.
13. Oyibo SO, Jude EB, Voyatzoglou D, Boulton AJM. Clinical characteristics of patients with diabetic foot problems: changing patterns of foot ulcer presentation. *Pract Diabet Int* 2001;19:10–12
14. Pendsey SP. Understanding diabetic foot. *Int J Diabetes Dev Ctries* 2010 Apr;30(2):75.
15. Dalla Paola L, Carone A, Vasilache L, Pattavina M. Overview on diabetic foot: a dangerous, but still orphan, disease. *Eur Heart J Suppl* 2015 Mar 1;17(suppl.A):A64–8.
16. Dalla Paola L, Faglia E. Treatment of diabetic foot ulcer: an overview. *Strategies for clinical approach*, *Curr Diabetes Rev* 2006;2:431–447.
17. Chan P, Stuart W, Hinchliffe R. New reporting standards are required to assess the impact of vascular intervention on patients with diabetic foot ulceration. *Eur J Vasc Endovasc Surg* 2015 Aug 1;50(2):139–40.
18. Hinchliffe RJ, Brownrigg JR, Apelqvist J *et al.* IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes. *Diabetes Metab Res Rev* 2016 Jan 1;32(S1):37–44.
19. International Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers. *Wounds International*, 2013. Available from: www.woundsinternational.com. Accessed on 21 April 2018.
20. Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. *J Diabetes Sci Technol* 2011 Nov;5(6):1591–5.
21. Raffetto JD. Which dressings reduce inflammation and improve venous leg ulcer healing. *Phlebology* 2014 May;29(suppl.1):157–64.
22. Edmonds ME, Foster AV, Sanders LJ. Stage 2: The High-Risk Foot. *A Practical Manual of Diabetic Foot Care*, 2nd Edn, 2008, pp. 45–80.
23. Jelinek A, DPM, Driver V. Current Concepts in Managing The Wound Microenvironment. *Podiatry Today* March 2006;19(9): 44–57.
24. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. *J Am Podiatr Med Assoc* 2002 Jan; 92(1):12–8.
25. Jude EB, Rogers AA, Oyibo SO, Armstrong DG, Boulton AJ. Matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in diabetic and venous ulcers. *Diabetologia* 2001 Aug 1;44:A3–A3.
26. Edwards JV, Bopp AF, Batiste S *et al.* Inhibition of elastase by a synthetic cotton-bound serine protease inhibitor: in vitro kinetics and inhibitor release. *Wound Repair Regen* 1999 Mar 1;7(2):106–18.
27. Honnegowda TM, Kumar P, Udupa EG, Kumar S, Kumar U, Rao P. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. *Plast Aesthet Res* 2015 Sep 1;2:243–9.
28. Brem H, Jacobs T, Vileikyte L *et al.* Wound-healing protocols for diabetic foot and pressure ulcers. *Surg Technol Int* 2003;11:85–92.
29. Peplow PV, Baxter GD. Gene expression and release of growth factors during delayed wound healing: a review of studies in diabetic animals and possible combined laser phototherapy and growth factor treatment to enhance healing. *Photomed Laser Surg* 2012 Nov 1;30(11):617–36.
30. Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. *Adv Wound Care* 2014 Oct 1;3(10):647–61.
31. Crovetti G, Martinelli G, Issi M *et al.* Platelet gel for healing cutaneous chronic wounds. *Transfus Apher Sci* 2004 Apr 1;30(2):145–51.
32. Lucey MR, Yamada T. Effect of Sucrose Octasulfate on Isolated Gastric Cells. In: *Sucralfate*. Springer, Boston, MA, 1995, pp. 103–109.
33. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM *et al.* Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. *Lancet Diabetes Endocrinol* 2017 Dec 20.
34. Richard JL, Martini J, Farail MB *et al.* Management of diabetic foot ulcers with a TLC-NOSF wound dressing. *J Wound Care* 2012 Mar;21(3):142–7.
35. Burch RM, McMillan BA. Sucralfate induces proliferation of dermal fibroblasts and keratinocytes in culture and granulation tissue formation in full-thickness skin wounds. *Agents Actions* 1991 Sep 1;34(1–2):229–31.
36. Volkin DB, Verticelli AM, Marfia KE, Burke CJ, Mach H, Middaugh CR. Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor. *Biochim Biophys Acta (BBA)-Protein Structure and Molecular Enzymology* 1993 Nov 10;1203(1):18–26.
37. Kulahin N, Kiselyov V, Kochoyan A *et al.* Dimerization effect of sucrose octasulfate on rat FGF1. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 2008 Jun 1;64(6):448–52.
38. White R, Cowan T, Glover D. Supporting evidence-based practice: a clinical review of TLC healing matrix, 2nd edn. London: MA Healthcare Ltd, 2015.
39. Coulomb B, Couty L, Fournier B. Evaluation of a matrix impregnated with NOSF in an *in vitro* dermal reconstruction model [article in French]. *Journal Plaies Cicatrisations* 2008;13:54–7.
40. Couty L, Fournier B, Laurensou C, Bouschbacher M, Aillaud C, Gogly B, Coulomb B. A NOSF (Nano-Oligosaccharide Factor) lipido-colloid dressing stimulates MMPs/TIMPs complexes formation leading to MMPs inhibition in an *in vitro* dermal equivalent model. *Wound Repair Regen* 2009 Jul 1;17(4):A64.

41. Bernard FX, Barrault C, Juchaux F, Laurensou C, Apert L. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipidocolloid dressing. *J Wound Care* 2005 May;14(5):215–20.
42. Bernard Fx, Juchaux F, Laurensou C. Effets d'un pansement lipidocolloïde sur la production de matrice extracellulaire par des fibroblastes dermiques humains in vitro. *JPC. Journal Plaies Cicatrisations* 2007;58:9–11.
43. Schmutz JL, Meaume S, Fays S *et al.* Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. *Int Wound J* 2008 May 1;5(2):172–82.
44. Meaume S, Truchetet F, Cambazard F *et al.* A randomized, controlled, double-blind prospective trial with a LipidoColloid Technology (Nano OligoSaccharide Factor) wound dressing in the local management of venous leg ulcers. *Wound Repair Regen* 2012 Jul;20(4):500–11.
45. Meaume S, Domp martin A, Lok C *et al.*, CHALLENGE Study Group. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomised controlled trial. *J Wound Care* 2017 Jul 2;26(7):368–79.
46. Augustin M, Herberger K, Kroeger K, Muenther KC, Goepel L, Rychlik R. Cost-effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. *Int Wound J* 2016 Feb 1;13(1):82–7.
47. Mütter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. *J Wound Care* 2017 Feb 1;26(Sup2):S4–15.
48. Wounds UK. Advertorial: Assessing efficacy of a TLC-NOSF dressing on DFUs: The Explorer study. *Wounds UK* 2013;9(1) Suppl 1
49. Tucker ME. Dressing Hastens Neuroischaemic Diabetic Foot Ulcer Healing. *Medscape* Jan 03 2018. Available at: www.medscape.com/viewarticle/890826 Accessed 24-4-18.
50. Diabetic Foot Australia. Did the Explorer trial find quicker foot ulcer healing with a sucrose octasulfate dressing? *Diabetic Foot Australia*. 2018. Available from: <https://www.diabeticfootaustralia.org/research-article/explorer-trial-find-quicker-foot-ulcer-healing-sucrose-octasulfate-dressing/> Accessed 24-4-18.

Introducing Kendall™ Gentle Border Foam Sacrum Dressings

Designed to help prevent and treat pressure injuries. They feature:

- A unique winged design for secure application
- Gentle silicone adhesive for minimal trauma and continued wear time
- Soft polyurethane foam to help relieve pressure
- High absorbency to maintain moisture balance
- Silky soft, waterproof topsheet with high moisture vapor transmission rate to reduce friction and shear



19cm

23.5cm



Antimicrobial line with PHMB, which helps inhibit MRSA, VRE, and other bacteria also available.

Medtronic Australasia Pty Ltd. 2 Alma Road, Macquarie Park NSW 2113 Australia. Toll Free: 1800 668 670
 Medtronic New Zealand Ltd. Level 3 - Building 5, Central Park Corporate Centre, 666 Great South Road, Penrose, Auckland 1051. Toll Free: 0800 377 807
medtronic.com.au © Medtronic. 2018 All Rights Reserved. 1197-01-18 #

Medtronic